Samsung Biologics Aims for Top Tier Beyond Production to Contract Development

New CDO Platform and Services Unveiled at BioUSA
S-Tensify Aims to Boost Productivity with 'High Concentration'
Spextailor Provides Customized CMC for Each Client

Samsung Biologics has introduced a new customer-tailored Contract Development Organization (CDO) platform and services through high-density cell culture, strengthening its overall CDMO capabilities by enhancing not only Contract Manufacturing Organization (CMO) but also CDO competitiveness.

Image of Samsung Biologics' new CDO platform 'S-Tensifavi'
[Photo by Samsung Biologics]

Samsung Biologics unveiled its new CDO platform, S-Tensify, at the 2024 BIO International Convention (BIO USA), the world's largest pharmaceutical and biotech conference held over four days from June 3 to 6 in San Diego, California. S-Tensify is a platform that supports the development of high-concentration biopharmaceuticals by applying advanced culture technology, expanding the scope of the N-1 perfusion technology previously applied to CMO in 2019.

The N-1 perfusion technology increases the inoculated cell density at the penultimate cell culture stage (N-1) by an average of 30 times, significantly enhancing productivity at the final cell culture stage (N). By simultaneously conducting cell culture and waste removal through perfusion culture, it overcomes the limitations of conventional methods where cell density could not be significantly increased due to waste accumulation inside the bioreactor.

Samsung Biologics expects that through S-Tensify, it will be able to expand its capabilities from traditional fed-batch culture methods to high-density culture methods with improved productivity, thereby providing enhanced CDO services.

Image of Samsung Biologics' new CDO service 'Selectailor'
[Photo by Samsung Biologics]

Samsung Biologics plans to conduct more proactive CDO marketing activities by launching new service branding. The new service is named Selectailor. Selectailor is a service that provides optimized, customized development packages for Chemistry, Manufacturing, and Controls (CMC) based on the unique material characteristics and development strategies of each client. It is a rebranding of the customized development solution launched in August last year.

Samsung Biologics aims to continuously expand its platform development and service areas to strengthen CDO competitiveness. Last year, it launched the proprietary transient expression platform S-Chojient, which supports the initial candidate material generation of biopharmaceuticals, and the material development support platform S-Glynn. Based on these activities, Samsung Biologics has signed a cumulative total of 116 CDO contracts through the first quarter of this year.

Min Hoseong, Vice President and Head of the CDO Development Center at Samsung Biologics, said, "By providing the culture methods and services that customers want, we expect that clients will be able to reduce the risks of biopharmaceutical development and enter the market more quickly. We will continue to develop innovative technologies and services to meet the diverse needs of our customers."